Company news
Silo Wellness Inc (CSE:SILO) news
Every Silo Wellness Inc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
August 18, 2026
Silo Pharma Granted European Patent Covering Novel PTSD Therapy
August 10, 2026
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
August 6, 2026
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
July 21, 2026
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
July 14, 2026
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
July 10, 2026
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
July 7, 2026
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
June 29, 2026
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
June 23, 2026
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 18, 2026
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
May 7, 2026
Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
April 29, 2026
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platfor...
April 22, 2026
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Tr...
April 20, 2026
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
April 6, 2026
Silo Pharma Announces Share Buyback Program
February 23, 2026
Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
February 18, 2026
Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
December 30, 2025
Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
November 17, 2025
Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
October 29, 2025
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
October 23, 2025
Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth
October 8, 2025
Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
October 6, 2025
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
October 1, 2025
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
September 30, 2025
Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management
September 29, 2025
Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of Business
September 28, 2025
Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
September 23, 2025
Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
September 16, 2025
Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
September 9, 2025
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
September 3, 2025
Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
August 21, 2025
Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway
August 19, 2025
Silo Wellness Appoints Defense Finance Veteran Richard Craven as CEO to Guide Strategic Transition to Born Defense
August 8, 2025
Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
August 5, 2025
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15
July 16, 2025
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
July 7, 2025
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion ...
June 25, 2025
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
June 11, 2025
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
June 5, 2025
Silo Wellness to Relist as Born Defense, a National Security Investment Issuer Focused on Ending Forever Wars and Upholding the Just War ...
June 2, 2025
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
May 21, 2025
Silo Pharma Announces Closing of $2 Million Public Offering
May 16, 2025
Silo Pharma Announces Pricing of $2 Million Public Offering
May 15, 2025
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
May 14, 2025
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
May 14, 2025
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
April 30, 2025
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug
April 28, 2025
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
March 26, 2025
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
February 26, 2025